Table 3 Comparative analysis of the therapeutic effect of UCMSCs on the median decrease in various parameters

AST

Group C

13 (− 10.5 to 40)

NS^CD

8 (− 12.3 to 24.5)

NS^CD

10 (2.5 to 26)

NS^CD

9.5 (− 0.3 to 17.5)

NS^CD

Group D

5 (0 to 27.5)

 − 1.5 (− 12.5 to 13.8)

7.5 (− 5.8 to 37.5)

 − 3 (− 24 to 7)

Group B

22 (4 to 104.3)

NS^BD

4 (− 14 to 25)

NS^BD

17.5 (− 10.3 to 42)

NS^BD

2 (− 5 to 17.5)

NS^BD

ALT

Group C

20 (− 3.5 to 153.5)

NS^CD

14.5 (2 to 21.5)

0.006^CD

1 (− 7 to 6.5)

NS^CD

 − 0.5 (− 6.5 to 6.8)

NS^CD

Group D

7 (2 to 23.25)

 − 2 (− 5.8 to 4)

1.5 (− 3.8 to 6.25)

2 (− 15 to 7)

Group B

32.5 (9.8 to 335.5)

0.005^BD

15 (− 2.5 to 27.5)

0.007^BD

5.5 (− 9 to 18.5)

NS^BD

0 (− 4 to 5.5)

NS^BD

PTA

Group C

0.5 (− 6.5 to 6.8)

NS^CD

2 (− 1 to 8.5)

NS^CD

7 (3 to 17)

NS^CD

6 (5.5 to 19)

NS^CD

Group D

0.5 (− 5.3 to 4)

4 (− 2 to 12)

4.5 (− 3 to 10.5)

 − 1 (− 2.5 to 0.5)

Group B

 − 1.5 (− 5.25 to 2)

NS^BD

1 (0 to 6)

NS^BD

7 (0 to 14)

NS^BD

3.5 (− 1 to 13)

NS^BD

MELD

Group C

0.5 (− 2 to 4)

NS^CD

1 (− 0.5 to 3)

NS^CD

6 (1 to 10)

0.020^CD

3 (2.5 to 7.5)

NS^CD

Group D

1 (− 1 to 3)

2 (1 to 4)

0.5 (− 1.3 to 4.3)

 − 1 (− 1 to 6.3)

Group B

0 (− 1 to 2)

NS^BD

3 (0 to 4)

NS^BD

5.5 (1 to 8.8)

0.030^BD

 − 1 (− 1.1 to 6)

NS^BD

AFP

Group C

32 (3 to 255)

0.021^CD

 − 2 (− 6 to 30)

NS^CD

 − 2 (− 36.8 to 12.5)

NS^CD

40.5 (15 to 66)

NS^CD

Group D

4.5 (1 to 27.8)

 − 1 (− 22 to 0.5)

0.5 (− 3.8 to 6.3)

0 (− 7.8 to 2.5)

Group B

9 (1 to 85)

NS^BD

 − 10 (− 76 to 81)

NS^BD

3 (− 8 to 4)

NS^BD

0 (− 2 to 0)

NS^BD